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Introduction
Myelodysplastic syndromes (MDS) constitute a hetero-
geneous group of myeloid neoplasms characterized by inef-
fective hematopoiesis, abnormal maturation of hematopoietic
cells, chromosomal abnormalities, and an increased risk of
evolution to acute myeloid leukemia (AML).1 The diagno-
sis of MDS is based principally on morphological examina-
tion of bone marrow cells, i.e., the percentage of blasts, the
type and degree of dysplasia, and the presence of ring
sideroblast. However, because morphological diagnosis can
be influenced by several factors, such as staining conditions
and the skill of the examining physician, it is still consid-
ered to be difficult to make a definitive diagnosis. A con-
sensus guideline for the diagnosis of MDS2 recommends
regular medical reviews with repeated blood counts and
morphological assessments at appropriate intervals, if the
morphological diagnosis remains uncertain. However, this
strategy does not consistently contribute to solving diag-
nostic dilemmas.
Previous reports indicate that immuno-phenotypic char-
acterization of bone marrow cells by flow cytometry (FCM)
may be feasible for the diagnosis of MDS. Maturing cells
as well as myeloblasts show immuno-phenotypic abnormali-
ties. In light of the accumulated data regarding immuno-
phenotypic aberrations in MDS, an international working
conference redefined the minimum diagnostic criteria for
MDS,3 which included multidimensional FCM analyses as
an important co-criterion for patients highly suspected to
have MDS. The two subsequent international working con-
ferences reported standardized FCM methods for applica-
tion to the diagnosis of MDS.4, 5
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Myelodysplastic syndromes (MDS) are a myeloid neoplasm characterized by abnormal differentiation, ineffective
hematopoiesis, and genetic instability with enhanced risk of transforming to acute myeloid leukemia (AML). The diagnosis of
MDS is principally made based on the percentage of blasts in the bone marrow and peripheral blood, type and degree of
dysplasia and the presence of ring sideroblasts. Recently, for making an accurate diagnosis of MDS, the aberrant antigen ex-
pression detection of hematopoietic cells by flow cytometry has been reported to be a useful. However, the diagnostic systems
utilized in those studies are rather complicated. We modified an existing flow cytometric scoring system (FCMSS) based on
aberrancies in the myeloid lineage and evaluated its usefulness in diagnosing various anemic disorders, including
myelodysplastic syndromes (MDS). The flow cytometric score was significantly higher in MDS patients than in those with other
anemic disorders, the exception being megaloblastic anemia (i.e., Vitamin B12 deficiency, folate deficiency). The data suggest
that our FCMSS may provide useful information for making the diagnosis of MDS and other anemic disorders.
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The possible use of a flow cytometric scoring system
(FCMSS) for the diagnosis of MDS was first explored by
Wells et al.6 They investigated the relationship between
immuno-phenotypic aberrations of the myelomonocytic
lineage and clinical courses. The FCMSS results correlated
well with the established International Prognostic Scoring
System (IPSS),7 indicating the score to be an independent
prognostic factor in MDS patients, including those who
underwent allogeneic stem cell transplantation. Van de
Loosdrecht et al8 also examined the Wells scoring system
and showed associations with transfusion dependence, dis-
ease progression and the World Health Organization (WHO)
Classification-Based Prognostic Scoring System (WPSS).9
Several additional studies investigated the potential fea-
sibility of flow-scoring systems for making a differential
diagnosis of low-grade MDS from non-clonal cytopenias.10-12
However, these systems were found to be too complex for
utilization in the general clinical setting. The present study
aimed to explore a simpler and more sensitive flow-scoring
system focusing on immuno-phenotypes of myeloblasts and
maturing granulocytes. Patients with low-grade MDS and
other forms of non-MDS anemia were evaluated by 4-color
FCM, and the usefulness of the flow-scoring system for




In total, 26 patients with MDS (15 males, 11 females)
and 18 with definite non-MDS anemia (7 males, 11 fe-
males) were studied. All patients underwent bone marrow
aspirations for diagnostic purposes prior to receiving sup-
portive care and gave informed consent. The research pro-
tocol was approved by the Institutional Review Boards of
Nagasaki University.
The MDS patients had a morphological diagnosis of re-
fractory anemia (RA) (n=15) or refractory cytopenia with
trilineage dysplasia (RCMD) (n=11), according to the
WHO classification.9 These patients were considered to
have low-grade MDS.
The non-MDS anemia patients had anemia of chronic
disorders (ACD) (n=5), pure red cell anemia (PRCA)
(n=1), aplastic anemia (AA) (n=2), autoimmune hemolytic
anemia (AIHA) (n=3), iron deficiency anemia (IDA) (n=1),
anemia of chronic renal failure (n=3), pernicious anemia
(n=2), or folate deficiency anemia (n=1).
Flow cytometric analysis
Four-color FCM was performed on a FACS Calibur
(Becton Dickinson) using a combination of monoclonal an-
tibodies that encompassed all differentiation stages of the
granulocyte lineage (myeloid blasts and maturing myeloid
cells) subpopulation. Seven panels of 4 monoclonal anti-
bodies were selected based on previous studies6 (Table 1).
All monoclonal antibodies used in this study were obtained
from BD (Biosciences, San Jose, CA, USA).
Bone Marrow was aspirated into a heparinized syringe,
and total nucleated bone marrow cells were isolated after
NH4 CI lysis of erythrocytes. Each sample was divided
into 7 test tubes, and stained with a combination of mono-
clonal antibodies conjugated with fluorescein isothiocyanate
(FITC), phycoerythrin (PE), peridin chlorophyll (PerCP),
and allophycocyanin (APC). The different cell compart-
ments (progenitor cells and granulocytes) were identified
using the CD45 vs Side Scatter (SS) gating method re-
ported by Wells et al.6 The granulocytic population was
identified as CD45dim/bright/SSCint/high. Myeloid progenitor cells
were identified as CD45dim/SSCdim.
Flow cytometric aberrancies
Aberrant expressions of certain antigens were defined
as a more than 0.5 log difference from normal expression
of that specific antigen. Aberrancies in myeloblasts and
granulocytes were evaluated per subpopulation (Table 2).
Flow cytometric analyses are summarized as follows: a sin-
gle aberrancy is depicted in lower case letters representing
a defined subpopulation of myeloid cells: b for blasts and
g for granulocytes, multiple aberrancies are depicted in
upper case letters (G).
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Table 1. Combination of antigen used in the FCM
Tube FITC PE PerCP APC
1 blank blank CD45 blank
2 CD20 CD10 CD45 CD34
3 HLA-DR CD11b CD45 CD10
4 CD16 CD13 CD45 CD14
5 CD14 CD33 CD45 CD19
6 CD34 CD7 CD45 CD56
7 CD15 CD34 CD45 HLA-DR
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Flow cytometric abnormal pathway
We analyzed the expression of granulocytic lineages and
maturation-associated antigens of BM cells quantified in a
previous study.6 Relationships between CD11b and HLA -
DR show in maturing myeloid cells that follow maturation
stages. Relationships between CD13 and CD16 show in the
maturing myeloid compartment. These relationships com-
pared with normal pathway.
Flow cytometric scoring
Flow cytometric data are translated into a numerical
flow-score from 0 to 3. We modified the scoring system of
Wells et al6 for simplification and greater sensitivity, by
setting a higher point for abnormalities in myeloblast cells
than mature granulocytes. Scores for the abnormalities gen-
erated for each cell type are summarized in Table 2. We
then evaluated flow data by division into four categories: the
presence of abnormal CD45 expression for myeloblasts, the
presence of abnormal CD16/CD13 pattern for granulocytes
(e.g. decrease of CD13 and CD16 double-positive population,
overexpression of CD13 in CD16-positive cells), the presence
of an abnormal HLA-DR/CD11b pattern for granulocytes (e.g.
overexpression of HLA-DR in CD11b-positive granulocytes),
and the presence of other abnormal expressions on granulocytes.
Finally, we calculated the sum of scores to serve as our
flow-score.
Statistical analysis
Proportions were compared between groups using either
a chi-square test or Fisher exact test. The Mann-Whitney U
test was used to compare flow-scores between the MDS
and non-MDS groups. Correlation analysis was performed
employing the Spearman rank correlation. Sensitivity, as
evaluated among MDS patients, was defined as the propor-
tion of patients with a flow-score above a specified cut-off
point for positivity (true positive rate). Specificity was
evaluated among patients with a diagnosis of non-MDS and
defined as the proportion of subjects with a flow score
below a certain criterion for positivity (also known as the
true-negative rate). Sensitivity and specificity are reported
for a range of cut-off values for the flow score to provide
information about the trade-offs in these quantities as the




Median age was 76.5 years (range, 34-87 years) in MDS
patients and 61 years (range, 26-87 years) in non-MDS pa-
tients, i.e., the MDS patients were older than the non-MDS
patients (Mann-Whitney, P<0.01). There was no difference
in the male to female ratio between the two disease groups
(chi-square, P=0.22). In non-MDS patients, adequate cytogenetic
data were available for 8 patients, and all were normal. In
MDS patients, adequate cytogenetic data were available for
24 patients, of whom 14 had a normal karyotype and 10
had an abnormal karyotype. IPSS scores were evaluable for
24 patients with MDS, all of whom showed IPSS less than
1.0. Age, sex, diagnosis category, hematological data,
cytogenetic data, and IPSS score are presented in Table 3.
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Table 2. Flow cytometry aberrancies in myeloblast and granulocytes
and the flow scores in MDS
Cell Aberrancies
Myeloid blasts
Granulocytes (maturing myeloid cells)
Abnormal expression of CD13
Abnormal expression of CD33
Expression of CD15
Abnormal expression of HLA-DR
Expression of lineage infidelity markers (CD7,19,56)
Abnormal CD16/CD13 pattern
Abnormal HLA-DR/CD11b
Abnormal expression of CD15














No flow cytometric aberrancies in both cells
A single aberrancy in granulocytes
A single lineage infidelity markers on either granulocytes
2 aberrancies in granulocytes
2 lineage infidelity markers on granulocytes
A single aberrancy in myeloid blasts
A single lineage infidelity markers on myeloid blasts
3 or more aberrancies in granulocytes
3 or more lineage infidelity markers on granulocytes
2 or more aberrancies in myeloid blasts
2 or more lineage infidelity markers on myeloid blasts
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Table 3. Characteristics of patients with MDS



















































































































































































































































































































































































































NA: not available; IPSS: International Prognostic Scoring System; secondary: secondary anemia, PRCA:pure red cell
anemia,AA: aplastic anemia, AIHA:autoimmune hemolytic anemia, IDA: iron deficiency anemia, CRF: anemia of
chronic renal failure, VitB12: pernicious anemia, and folate: folate deficiency anemia.
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Aberrant immuno-phenotype identified by flow cytometric
analysis
Some examples of normal and aberrant granulopoiesis
are shown in Figure 1. In the analysis of myeloid progenitor
cells, a lineage infidelity marker was observed on myeloblasts
in 11% of MDS cases (3 of 26), with co-expressed markers
such as CD7, CD56 and CD19. Among non-MDS patients,
5.5% (1 of 18) had a lineage infidelity marker on CD34+
myeloid blasts. One patient with aplastic anemia showed
expression of infidelity marker CD19 on myeloblasts in ad-
dition to abnormal granulocytic maturation. Other aberrant
phenotypes on myeloid blasts observed only in MDS pa-
tients included low expressions of CD14 and CD11b, and
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Figure 1. The pattern of normal and aberrant granulopoiesis. (A) The relationship between CD16
(x-axis) and CD13 (y-axis) for granulocytes. Development from immature to mature granulocytes
is illustrated by a sickle-shaped yellow arrow in the graph of the control sample. The graph of pa-
tient with MDS shows aberrant antigen expression and maturation compared with the normal con-
trol. (B) The relationship between HLA-DR (x-axis) and CD11b (y-axis) for granulocytes. A yel-
low arrow in the control sample depicts normal maturation of immature blasts toward maturing
granulocytes and monocytes. The granulocytic subpopulation in the MDS sample shows abnormal
pathway of CD11b. (C) Expression of infidelity antigen CD7 (y-axis) on myeloid progenitors, de-
fined by CD45dimSSCdim and CD34 expression, is depicted.
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over-expressions of CD13, CD33, CD34 and HLA-DR.
In the immuno-phenotype analysis of maturing myeloid
cells (granulocytes), 50% of MDS (13 of 26), 53% of RA
(8 of 15) and 45% of RCMD (5 of 11) patients showed ab-
normal expressions. Abnormal relations between CD16 and
CD13 and between HLA-DR and CD11b were prominent
in MDS patients. Other abnormalities of maturing myeloid
cells included an abnormal pathway, lack of CD15, low
stage 2 cells, and abnormal expression of CD38/CD56.
Among patients with non-MDS anemia, immuno-phenotypic
abnormalities of maturing myeloid cells (granulocytes) were
found in 22% (4 of 18), with abnormal relations between
CD16 and CD13, and also between HLA-DR and CD11b in
2 patients with pernicious anemia, one with folate deficiency,
and one with anemia of chronic disorders. A patient with
aplastic anemia showing expression of an infidelity marker
(CD19) on myeloblasts also had abnormal granulocytic matu-
ration, including an abnormal pathway with 3% of heterogeneous
cells expressing CD38 strong positive/CD45dim/CD19positive.
Flow cytometric results for individual patients are summa-
rized in Table 4.
Flow-score
Results of the flow-score are also summarized in Table
4. The scores were compared between MDS and non-MDS
patients. Seventy-three percent of MDS patients (19 of 26),
but only 28% of non-MDS patients (5 of 18), had flow-
scores of 1 or greater. The relationships between the flow-
score and patient groups are depicted in Figures 2 and 3.
The median flow-score was 1 (range, 0-4) in MDS and 0
(range, 0-3) in non-MDS anemia, i.e., the former score was
significantly higher than the latter (Mann-Whitney, P=0.03).
Among MDS patients, there was no flow-score difference
between RA and RCMD (Mann-Whitney, P=0.81). Among
non-MDS patients, high scores were observed in one
patient with anemia of chronic disorders, one with aplastic
anemia, and 3 with megaloblastic anemia. Because all 3 pa-
tients with megaloblastic anemia had flow-scores of 1 or
greater, we compared flow-scores between MDS and non-
MDS cases excluding these 3 with megaloblastic anemia.
The flow-score distribution was significantly higher in
MDS than in non-MDS cases when the 3 megaloblastic
anemia cases were excluded (Mann-Whitney, P=0.005).
(Figure 3). Comparison of the scores between RA or
RCMD and non-MDS excluding the 3 megaloblastic ane-
mia cases, revealed these scores to also be significantly
higher in RA (Mann-Whitney, P=0.01) or RCMD (Mann-
Whitney, P=0.02) cases than in the non-MDS cases. There
was no correlation between flow-score and IPSS score
90











decrease of CD13 and CD16 double-positive population
overexpression of CD13 in CD16-positive cells
Abnormal HLA-DR/CD11b
（overexpression of HLA-DR in CD11b-positive granulocytes）
Abnormal expression of CD15















Figure 2. Flow-score comparison between MDS and non-MDS.
Flow scores were calculated according to the scoring system
shown in Table 2. Horizontal bars represent median values.
Figure 3. Flow-score comparisons between RA and RCMD, be-
tween RA and non-MDS, and between RCMD and non-MDS.
Flow scores were calculated according to the scoring system
shown in Table 2. Horizontal bars represent median values.
Daisuke Ogawa et al.: Flow cytometric scoring system for MDS diagnosis 91
Table 5. Immunophenotipic aberration on FCM and Flow-scoring


















































































































































































































































































































































































Results of flow cytometric analysis are summarized as follows; a single aberrancy is depicted in lower case representing a defined subpopulation of mye-
loid cells: b for blasts, g for granulocytes, multiple aberrancies are depicted in upper case (B and G), the lineage infidelity markers within normal blast
percentages is depicted as nb, the lineage infidelity marker that is expressed on each definition is added to the marker.
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(data not shown). The best diagnostic sensitivity and speci-
ficity of our flow-score system for low-grade MDS was ob-
served when a cut-off score of 1 used, yielding a specificity
of 73.1% with 72.2% sensitivity.
Discussion
In this study, we showed flow cytometric aberrancies to
be frequent in the myeloid lineage of patients with low-
grade MDS as compared to those with non-clonal forms of
anemia. We also showed our flow-score to be useful for di-
agnosing MDS and other non-clonal anemic disorders, with
the exception of megaloblastic anemia.
Flow cytometry is regarded as a potential new tool that
may add significantly to diagnosis and prognosis determi-
nation for MDS patients. Herein, we studied the maturation
pattern of myeloid cells by evaluating surface antigen ex-
pression in patients with anemia including MDS. Bone
marrow samples from patients diagnosed as having MDS,
AIHA, AA, PRCA or IDA were analyzed with a panel of
antibodies targeting various differentiation stages of the
granulocytic lineage. Consistent differentiation patterns were
seen in most of the anemic disorders except for MDS, AA,
Vitamin B12 deficiency and folate deficiency. Of note, patients
with disorders other than MDS also exhibited aberrancies in
maturing granulocytes. In 17 of 26 MDS patients diagnosed
according to the WHO criteria, aberrant differentiation an-
tigen expression was demonstrated in myeloid blasts and
granulocytes.
In our study, aberrant immuno-phenotypes of maturing
granulocytes were detected in about 40% of MDS patients,
implying that this finding could provide a useful parameter
for the differential diagnosis of various anemic disorders.
However, since aberrancies in granulocytes were also de-
tectable in AA, Vitamin B12 deficiency, folate deficiency
and anemia of chronic disorders, careful interpretation is
necessary. Therefore, at present, cytomorphology is still
considered to be the mainstay for diagnosing MDS.
The present study has several limitations. First, the num-
ber of patients examined was too small to allow differences
to be statistically confirmed. Second, we included a limited
number of immuno-phenotypic markers in our flow-scoring
system. Recently, two studies demonstrated the utility of
their own FCMSS for diagnosing low-grade MDS based on
abnormal multi-lineage antigen co-expression in CD34+
blasts, showing good sensitivity and specificity for distin-
guishing low-grade MDS from non-clonal cytopenia.12,13
Another report suggested CD38 expression on CD34+ cells
to be of value for diagnosing MDS based on a single
marker.14
In conclusion, our simple FCMSS focusing on myeloblasts
and granulocytes may be useful for distinguishing patients
with low-grade MDS from those with other types of ane-
mia. There is as yet no standard FCMSS that efficiently
distinguishes MDS from other non-clonal cytopenias, and
our simple scoring system may provide a basis for the de-
velopment of standard protocol.
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